Immediate Impact
25 standout
Citing Papers
Epigenetic drugs in cancer therapy
2025 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Works of Laura Leroy being referenced
Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?
2019
Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Laura Leroy | 16 | 27 | 3 | 5 | 8 | 32 | |
| Y. Runglodvatana | 20 | 34 | 5 | 8 | 8 | 39 | |
| Muhammad Saad Hamid | 18 | 15 | 3 | 6 | 9 | 32 | |
| Beatriz Rojas | 7 | 18 | 5 | 5 | 6 | 29 | |
| Jade M. van Berge Henegouwen | 17 | 25 | 5 | 5 | 12 | 36 | |
| Karina Vianna | 19 | 36 | 7 | 7 | 6 | 39 | |
| Yingmei Guo | 10 | 15 | 5 | 14 | 9 | 37 | |
| S. Khosrowjerdi | 12 | 19 | 3 | 7 | 8 | 24 | |
| Zhanyu Pan | 14 | 20 | 4 | 3 | 6 | 32 | |
| Sean Dulloo | 38 | 14 | 4 | 9 | 11 | 47 | |
| K Kambartel | 9 | 25 | 1 | 4 | 11 | 30 |
All Works
Login with ORCID to disown or claim papers
Loading papers...